Evaluation of rhesus rotavirus vaccine (MMU 18006) in infants and young children.
Evaluation of rhesus rotavirus vaccine (MMU 18006) in infants and young children.
复制标题
婴幼儿恒河猴轮状病毒疫苗（MMU 18006）的评价。
DOI：
10.1093/infdis/153.5.823
复制
发表时间：
1986
期刊：
影响因子：
--
通讯作者：
Kapikian,AZ
中科院分区：
文献类型：
--
作者：
Anderson,EL;Belshe,RB;Bartram,J;Crookshanks-Newman,F;Chanock,RM;Kapikian,AZ
一项针对幼儿和婴儿（8 个月至 61 个月）的安慰剂对照研究对口服恒河猴轮状病毒疫苗进行了评估。 13 名儿童接种了轮状病毒疫苗，10 名儿童作为对照组。该疫苗耐受性良好。疫苗接种者和对照组之间出现体温≥37.8℃、呕吐、腹泻或咳嗽的儿童天数没有显着差异。疫苗接种者儿童流鼻涕的天数明显多于对照组。两岁以下的疫苗接种者比对照组儿童排出的粪便数量更多，而且疫苗接种者的半成形和不成形粪便明显多于接受安慰剂的儿童。所有接受测试的十二名儿童均呈病毒排出阳性。病毒排出高峰发生在疫苗接种后第三天和第五天。第八天，在获得粪便样本的儿童中，超过一半仍在散发轮状病毒。两岁以下的儿童比两岁以上的儿童在粪便中排出更多的轮状病毒。通过空斑减少、试管中和、补体固定和/或免疫粘附血凝测定，所有 13 名疫苗接种者的抗体滴度均增加了四倍或更高。
Orally administered rhesus rotavirus vaccine was evaluated in a placebo-controlled study in young children and infants (ages, eight months to 61 months). Thirteen children received the rotavirus vaccine, and ten children served as the control group. The vaccine was well tolerated. There were no significant differences between the vaccine recipients and the control group in the number of child-days with temperatures ⩾37.8 C, vomiting, diarrhea, or cough. There were significantly more child-days of rhinorrhea among the vaccine recipients than there were among the control group. The vaccine recipients under two years of age passed a larger number of stools than did the children in the control group, and vaccine recipients had significantly more semiformed and unformed stools than did the children receiving the placebo. All twelve of the children tested were positive for viral shedding. Peak viral shedding occurred on days three and five postvaccination. On day eight, over one-half of the children from whom a stool specimen was obtained were still shedding rotavirus. Children less than two years old shed more rotavirus in their stool than did children more than two years old. All 13 vaccine recipients had a fourfold or greater rise in titer of antibody as measured by plaque reduction, tube neutralization, complement fixation, and/or immune adherence hemagglutination.